Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

RHEUMATOLOGY IN PERSPECTIVE · RHEUMAVIEW

SJÖGREN’S · Clinical trials

What Sjögren clinical trials really tell us

How to read encouraging findings, negative results and unanswered questions · Trial update: 11 November 2026

Research is moving forward, but “the trial worked” can mean several different things. A treatment may improve organ-related disease activity without clearly improving fatigue or dryness. This guide explains the main studies and how to connect their results to a real treatment goal. Research doses are described in the professional chapter, not offered as instructions for self-treatment.

What makes a trial result convincing?

Look for a fair comparison and a question chosen in advance. In a randomized trial, assignment to treatment or a comparison group occurs by chance. Blinding reduces the influence of expectations. Researchers specify the main outcome and when it will be measured.

People can improve in both groups because of background care, natural fluctuation and other factors. The important treatment estimate is the difference between groups, not simply how much the active group improved. A small exploratory trial is useful, but carries more uncertainty than a larger confirmatory study.

Back to contents ↑

What are the scores measuring?

ESSDAI describes systemic disease activity assessed by clinicians. ClinESSDAI excludes its laboratory domain. ESSPRI describes patient-reported dryness, fatigue and pain. Tear tests and saliva measurements answer narrower questions about function. CRESS and candidate STAR combine several kinds of outcomes. [R28] [R33] [R34]

These are different windows on the disease. Improvement in one does not guarantee improvement in all. Ask whether the trial’s main outcome resembles the problem you want treatment to change. A lower antibody level alone is not proof that daily life has improved.

Back to contents ↑

Hydroxychloroquine: what did JOQUER show?

JOQUER did not show an advantage for HCQ on its main combined dryness, pain and fatigue outcome at 24 weeks. It therefore does not support a promise that HCQ reliably improves this symptom combination for everyone. [R20]

That does not answer every question about inflammatory joints, skin manifestations or another associated disease. If you take HCQ, the relevant next question is what it was prescribed to treat and how that goal is being reviewed, rather than changing it because of one study headline.

Back to contents ↑

Rituximab and abatacept: why negative findings matter

TRACTISS did not demonstrate the expected broad fatigue or oral-dryness benefit from rituximab. A large abatacept study also failed its main systemic-activity endpoint. Both findings matter even though the drugs act on plausible immune pathways. [R21] [R22]

They help prevent treatment based only on theory. They do not settle every uncommon, serious organ complication. Nor does an isolated improvement in a laboratory or saliva measure turn a negative main result into a successful trial. Ask whether the proposed use matches the question that was actually tested.

Back to contents ↑

Belimumab and treatment sequences

An early belimumab study reported improvement in some participants but had no placebo group. A later small randomized study of belimumab followed by rituximab showed deeper B-cell depletion and an encouraging disease-activity pattern. It was not definitive proof of routine clinical benefit. [R47] [R25]

Removing immune cells more completely is not itself the goal of treatment. The questions are whether people function better, organs are protected and the benefit outweighs infections and other harms. Combination treatment also needs its own safety evidence.

Back to contents ↑

RepurpSS and NECESSITY: new uses for established medicines

RepurpSS-I and the 2026 RepurpSS-II study tested leflunomide with HCQ in adults with active systemic disease. Both found a benefit on their disease-activity outcome; the second study included 46 people. [R23] [R24]

This is encouraging replication, but not proof for every person whose main difficulty is fatigue or dryness with little systemic activity. Familiar medicines still have meaningful risks and monitoring needs. Leflunomide also raises important reproductive considerations. “Existing” and “affordable” do not mean suitable for unsupervised use.

HCQ combinations: a new, preliminary signal. The NECESSITY trial tested hydroxychloroquine (HCQ) with mycophenolate mofetil or leflunomide. Its ACR 2026 abstract reported a week-24 STAR composite response in about 54% and 52%, compared with 24% on placebo. A composite combines several aspects of disease; it does not mean that each symptom improved. [R64]

The clearest separation was in the group with high symptoms but low systemic activity. Results were inconclusive in the smaller group with more systemic activity and when another composite, CRESS, was used. Serious adverse events were more frequent in the HCQ–mycophenolate group. These conference findings merit discussion with a rheumatologist, but do not justify starting or changing a combination on your own. [R64]

Back to contents ↑

Ianalumab: a positive main outcome is not every outcome

Status: Phase III results are published; regulatory review is ongoing. A modest benefit for systemic disease activity has been shown, but a clear benefit for dryness, fatigue and pain has not been established. [R61] [R65] [R66]

Ianalumab targets BAFF-R and depletes B cells. The NEJM report included 275 and 504 randomized participants in NEPTUNUS-1 and NEPTUNUS-2. Monthly treatment improved ESSDAI, a clinician-rated measure of systemic activity, by about 1.3 and 1.0 points more than placebo. Key symptom measures, ESSPRI and SSSD, and the proportion with a large ESSDAI improvement did not differ significantly. These results help separate control of organ inflammation from how someone feels day to day. [R61]

Novartis reports FDA priority review and submissions in the United States, Europe, China and Japan. Its 10 November update still describes review as ongoing. Priority review and Breakthrough Therapy designation do not make the drug available as an approved Sjögren treatment. [R43] [R65] [R66]

Back to contents ↑

Dazodalibep: separate studies for separate needs

The phase II program tested both people with active systemic disease and people with substantial symptoms but less systemic activity. Those are different populations and outcomes. [R28]

Status: Phase III OASIZ-301 showed a benefit for systemic activity; the separate OASIZ-303 symptom study is still ongoing. Dazodalibep remains investigational. [R62]

Dazodalibep interrupts CD40L-related immune communication. The 11 November OASIZ-301 report describes 648 randomized participants. At week 48, ESSDAI fell by 5.6 points with treatment every four weeks, 5.2 every twelve weeks and 3.8 with placebo. The extra reductions over placebo were 1.8 and 1.4 points, respectively; both were statistically significant. [R62]

The every-four-week regimen also improved reported dryness compared with placebo. This report does not establish a separate benefit for pain or fatigue. Earlier phase II symptom findings remain useful background, while OASIZ-303 is needed to answer the distinct phase III question in people selected for a high symptom burden. [R28] [R62]

Back to contents ↑

Telitacicept: promising results with a country-specific milestone

Telitacicept has phase II evidence and a reported positive phase III study conducted in China. The phase III study enrolled 381 participants and compared two doses with placebo alongside standard treatment. [R30] [R31]

RemeGen’s June 2026 disclosure reports Chinese approval for adults with active disease on conventional treatment. That statement concerns a particular country and indication; it does not confer authorization elsewhere. The complete risks, applicability to different populations and results of the international program must still be assessed separately. [R32] [R41]

Back to contents ↑

Nipocalimab and efgartigimod: similar target, different evidence

Both approaches affect FcRn, a pathway involved in maintaining IgG antibodies in circulation. DAHLIAS found a systemic-activity benefit with the higher tested nipocalimab dose, while the lower dose did not show significant benefit. [R33]

Status: The phase III UNITY study was stopped for futility. Efgartigimod is not an established treatment for Sjögren’s disease. [R63]

Efgartigimod affects FcRn, a pathway that helps maintain circulating IgG antibodies. The small RHO trial produced an encouraging early composite-response signal without a formal hypothesis test. However, on 8 October 2026, argenx announced that an independent committee recommended stopping UNITY because it was unlikely to meet its main week-48 clinical disease-activity goal. The reason was insufficient evidence of benefit, and no new safety signal was reported. [R34] [R63]

Back to contents ↑

Iscalimab, signalling drugs and low-dose IL-2

Iscalimab’s systemic-activity findings were stronger than its symptom findings. Remibrutinib also showed a systemic signal without a clear symptom benefit. A trial of filgotinib, lanraplenib and tirabrutinib did not meet its main goal. These results show why a promising mechanism is not enough. [R35] [R36] [R37]

A small low-dose IL-2 trial reported benefit, but needs broader confirmation. A small study’s reassuring safety results cannot exclude uncommon harms. These are research findings, not a menu of interchangeable treatments to try independently. [R38]

Back to contents ↑

What can a dryness study prove?

A small diquafosol study in Sjögren dry eye examined tear volume after a single drop. That can answer a short-term local question, but cannot demonstrate regeneration of glands or long-term control of the whole disease. [R39]

Check whether a dry-eye or dry-mouth trial actually included people with Sjögren. Studies in other causes of dryness may help inform care, but their results are indirect. Better moisture, symptom relief and prevention of tissue damage are related goals that require different measurements.

Back to contents ↑

How should a trial influence my next decision?

Identify how closely you match the participants, which outcome matters to you, the extra benefit over the comparator and the remaining uncertainty. Then consider safety, treatment burden, local authorization and access.

For trial participation, check the current registry and the individual site. “Active” can mean follow-up is continuing while recruitment is closed. A registry entry is not evidence that treatment works. The pipeline chapter provides dated study cards and explains questions about visits, randomization, background treatment and follow-up after participation. [R41] [R44]

Back to contents ↑

Sources

  1. [R20] Gottenberg et al. Hydroxychloroquine: JOQUER randomized trial (2014)
  2. [R21] Bowman et al. Rituximab: TRACTISS randomized trial (2017)
  3. [R22] Baer et al. Abatacept phase III randomized trial (2021)
  4. [R23] van der Heijden et al. RepurpSS-I (2020)
  5. [R24] Wong et al. RepurpSS-II (2026)
  6. [R25] Mariette et al. Sequential belimumab and rituximab (2022)
  7. [R26] Bowman et al. Ianalumab phase 2b dose-finding trial (2022)
  8. [R27] Novartis: NEPTUNUS-1/2 phase III results presented at ACR (29 October 2025)
  9. [R28] St Clair et al. Dazodalibep phase II: two populations (2024)
  10. [R29] Amgen: OASIZ 301 positive topline announcement (22 September 2026)
  11. [R30] Xu et al. Telitacicept phase II (2023 online; 2024 issue)
  12. [R31] Vor Bio/RemeGen: China telitacicept phase III ACR data (14 October 2025)
  13. [R32] RemeGen statutory disclosure: telitacicept Sjögren indication approval (9 June 2026)
  14. [R33] DAHLIAS: nipocalimab phase II (Lancet 2025)
  15. [R34] Peene et al. Efgartigimod RHO proof-of-concept trial (2026)
  16. [R35] Fisher et al. Iscalimab TWINSS phase 2b (2024)
  17. [R36] Dörner et al. Remibrutinib LOUiSSE phase II (2024)
  18. [R37] Price et al. Filgotinib, lanraplenib and tirabrutinib phase II (2022)
  19. [R38] He et al. Low-dose interleukin-2 randomized trial (2022)
  20. [R39] Yokoi et al. Diquafosol tear-volume pilot in Sjögren dry eye (2016)
  21. [R41] ClinicalTrials.gov: named late-stage Sjögren programs
    Additional source recordshttps://clinicaltrials.gov/study/NCT05349214https://clinicaltrials.gov/study/NCT06104124https://clinicaltrials.gov/study/NCT06245408https://clinicaltrials.gov/study/NCT05673993https://clinicaltrials.gov/study/NCT07404865https://clinicaltrials.gov/study/NCT04968912https://clinicaltrials.gov/study/NCT06741969https://clinicaltrials.gov/study/NCT05817669https://clinicaltrials.gov/study/NCT07760818https://clinicaltrials.gov/study/NCT03905525https://clinicaltrials.gov/study/NCT04035668https://clinicaltrials.gov/study/NCT03100942https://clinicaltrials.gov/study/NCT02446249
  22. [R43] Novartis: FDA Breakthrough Therapy designation for ianalumab (16 January 2026)
  23. [R44] Sjögren Foundation: find a clinical trial
  24. [R46] Novartis Q3 2025 results: NEPTUNUS numerical table, slide 17
  25. [R47] Mariette et al. BELISS open-label phase II study (2015)
  26. [R61] NEPTUNUS-1/2: randomized phase III trials, NEJM (21 October 2026)
  27. [R62] Amgen: OASIZ-301 numerical phase III results (11 November 2026)
  28. [R63] argenx: phase III UNITY stopped for futility (8 October 2026)
  29. [R64] Mariette et al. NECESSITY: ACR 2026 abstract LB15
  30. [R65] Novartis Q1 2026: ianalumab priority review and regulatory submissions (28 April 2026)
  31. [R66] Novartis: NEPTUNUS extension and pending regulatory review (10 November 2026)

Personal educational publication by Olga Goodman, MD. This is not a clinic portal or an emergency service. Any private expert service is separate from clinic accounts and insurance billing. Reuse requires attribution and a link to the original publication.

dr.rheumaview.com · Olga Goodman, MD

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Clinical evidenceClinical trialsSjögren disease